Valeant Pays $12M To Settle Wellbutrin Antitrust Claims

Law360, New York (February 15, 2013, 7:14 PM ET) -- Valeant Pharmaceuticals International Inc. will pay at least $11.75 million to settle a class action brought by health insurers and other indirect purchasers, accusing it of conspiring to stifle generic versions of antidepressant Wellbutrin XL and monopolize the market, according to documents filed Friday in Pennsylvania federal court.

Under the terms of the settlement, which is still subject to court approval, Valeant will pay either $11.75 million plus the lesser of either $500,000 or 50 percent of the cost of notifying class members, or 30 percent of...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required

Case Information

Case Title

MEIJER, INC. et al v. BIOVAIL CORPORATION et al

Case Number

2:08-cv-02431

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

MARY A. MCLAUGHLIN

Law360 Coverage

Date Filed

May 23, 2008


Case Title

PLUMBERS AND PIPEFITTERS LOCAL 572 HEALTH AND WELFARE FUND v. BIOVAIL CORPORATION et al

Case Number

2:08-cv-02433

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Anti-Trust

Judge

MARY A. MCLAUGHLIN

Law360 Coverage

Date Filed

May 23, 2008

Sections

Law Firms Mentioned

Companies Mentioned

Government Agencies Mentioned

Related Articles